Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BiofilmEradicate

Financiado

Modification of liposomic nano-carriers: a novel strategy for improved drug-deli...

Modification of liposomic nano-carriers: a novel strategy for improved drug-delivery and eradication of bacterial biofilms Bacterial biofilms are widespread, both as infections in humans and on devices that have come in contact with infected tissue, and pose a major health and economic burden. Such biofilms are difficult to treat as they present stron... ver más

31/03/2024

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1

I+D

Cerrada hace 3 años

0% 100%

1 Participantes

WEIZMANN

150.00K€ | Lider

Proyectos interesantes

NanoDeliveryEnhance Novel functionalization of liposomic nano-vehicles for stron... 150K€ Cerrado

OatLive Mix and Match: One-step activation for targeted drug deliver... 150K€ Cerrado

SAF2016-79230-R NUEVA ESTRATEGIA MULTI-ETAPA PARA LA LIBERACION ORAL DE BIOM... 97K€ Cerrado

AIDViC Antibiotic intracellular delivery via virus like carriers 149K€ Cerrado

RTI2018-101309-B-C21 SINTESIS Y CARACTERIZACION DE NANOGHOSTS COMO SISTEMAS NOVED... 154K€ Cerrado

BIO2014-61515-EXP ANTIBIOTICOS VIVOS FRENTE A PATOGENOS INTRACELULARES 30K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 22 meses Fecha Inicio: 2022-05-30
Fecha Fin: 2024-03-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Bacterial biofilms are widespread, both as infections in humans and on devices that have come in contact with infected tissue, and pose a major health and economic burden. Such biofilms are difficult to treat as they present strong resistance to drug delivery, due to a dense, hydrated polysaccharide/protein matrix in which the bacterial communities encase themselves, and from the bacterial membrane itself. Liposomes stabilized by poly(ethylene glycol), PEG moieties, the current gold-standard and most commonly used means of stabilization, are versatile drug-delivery vehicles, but such PEGylation is associated with significant shortcomings, greatly reducing the efficiency of PEGylated liposomes for biofilm treatment. Here we explore a novel strategy to improve such drug delivery and treatment of biofilms. In particular, is it effective? is it efficient? Can it be readily applied both in vitro (for which we have some promising preliminary indications) - as for infected biomedical devices - and, crucially, in vivo? What is the IPR position for future exploitation of this new drug delivery strategy? These questions illustrate the high-risk/high-gain nature of this proposal, and are systematically addressed in this proposal through several inter-related work packages. Success of our project in demonstrating that our novel drug-encapsulating vehicles can efficiently treat and eradicate bacterial biofilm infections would not only have benefits affecting large populations, but also tap into a large drug-delivery market.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores